학술논문

Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial
Document Type
Article
Author
Halton, JacquelineBrandão, Leonardo RLuciani, MatteoBomgaars, LisaChalmers, ElizabethMitchell, Lesley GNurmeev, IldarSharathkumar, AnjaliSvirin, PavelGorbatikov, KirillTartakovsky, IgorSimetzberger, MonikaHuang, FengleiSun, ZhichaoKreuzer, JörgGropper, SavionReilly, PaulBrueckmann, MartinaAlbisetti, ManuelaNurmeev, IldarSafina, AsiyaZapletal, OndrejBrandão, Leonardo RKuhn, TomasVotava, TomasFelgenhauer, JudySharathkumar, AnjaliSvirin, PavelAmid, AliHalton, JacquelineGorbatikov, KirillSaracco, PaolaKiss, CsongorHalimeh, SusanReschke, MadlenWulff, BeateDavid, MicheleNovak, ZbynekTrunina, InnaAlbisetti, ManuelaFrisk, TonyGlosli, HeidiGroll, AndreasLvova, OlgaSasmaz, IlgenSosothikul, DarintrZilinskaite, VirginijaCockrell, ErinDigtyar, ValeriyHadacova, IvanaPalmu, SauliPawar, AnjaliAnnichino Bizzacchi, Joyce MariaCaliskan, UmranCelkan, TirajeDmytriiev, DmytroDruzgal, Colleen HarkinsOnelda Elena, GracielaKattamis, AntonisKavakli, Ramazan KaanMale, ChristophOzdemir, NihalVan Damme, AnZvereva, TatianaAarli, AanenParedes Aguilera, Rogelio AlejandroAytac, SelinCarneiro, JorgeChistolini, AntonioMazzucconi, Maria GabrielaCorrales-Medina, FernandoCouturaud, FrancisCroteau, Stacey ETrenor III, CameronDamgaard, MichaelDixon, NataliaGalustyan, AnnaHak, JiriHoffmann, MarianneKupesiz, AlphanLabarque, Veerlevan Geet, ChristelLin, Ming-ChihFu, Yun-ChingLoggetto, SandraMondelaers, VeerleOdri-Komazec, IrenaRevel-Vilk, ShoshanaSevilla, JulianFuzzato Silva, LucianoKerr Saraiva, JoséMontes Tapia, Fernando FelixWoods-Swafford, Wendy
Source
The Lancet Haematology; January 2021, Vol. 8 Issue: 1 pe22-e33, 12p
Subject
Language
ISSN
23523026
Abstract
Dabigatran etexilate is a direct oral anticoagulant with potential to overcome the limitations of standard of care in children with venous thromboembolism. The aims of this clinical trial were to study the appropriateness of a paediatric dabigatran dosing algorithm, and the efficacy and safety of dabigatran dosed according to that algorithm versus standard of care in treating children with venous thromboembolism.